SCHEMBL640039

SCHEMBL640039

S=c1[nH]cc(-c2ccc3c(c2)OCO3)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 1/20 0.48
KDM4E B2RXH2 5/20 0.47
GFER P55789 2/20 0.47
GAA P10253 1/20 0.47
PDE10A Q9Y233 1/20 0.46
HDAC8 Q9BY41 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 4/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
MCL1 Q07820 1/20 0.43
SNCA P37840 1/20 0.43
NISCH Q9Y2I1 1/20 0.42
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639509 0.90 KDM4E (0.47) DCUN1D1KDM4EGFERGAAPDE10A
SCHEMBL640277 0.77 DYRK1A (0.46) KDM4EGFERGAAHDAC8SMN1; SMN2
SCHEMBL11175737 0.76 DCUN1D1 (0.53) DCUN1D1KDM4EPDE10ASMN1; SMN2ALDH1A1
SCHEMBL3749369 0.71 CYP3A4 (0.44) GAAALDH1A1MAPT
SCHEMBL17520498 0.70 ALDH1A1 (0.57) DCUN1D1KDM4EPDE10ASMN1; SMN2HSD17B10
SCHEMBL15425091 0.70 ADORA2A (0.51) KDM4EPDE10ASMN1; SMN2ALDH1A1POLB
SCHEMBL638781 0.69 GFER (0.53) KDM4EGFERGAAHDAC8ALDH1A1
SCHEMBL10057827 0.69 SNCA (0.77) DCUN1D1KDM4ESMN1; SMN2HSD17B10ALDH1A1
SCHEMBL640250 0.69 KDM4E (0.49) KDM4EGFERGAAHDAC8SMN1; SMN2
SCHEMBL22162812 0.68 CA12 (0.58) DCUN1D1KDM4ESMN1; SMN2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US claimed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US claimed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP claimed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO claimed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO claimed
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US disclosed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP disclosed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO disclosed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF TYR, TH, PAH DCUN1D1 2055/4885KDM4E 582/4885GFER 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.